Litigation Details for Neurocrine Biosciences, Inc. v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

« Back to Dashboard

Neurocrine Biosciences, Inc. v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Docket	1:21-cv-01067	Date Filed	2021-07-23
Court	District Court, D. Delaware	Date Terminated	2023-10-05
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,065,952; 10,844,058; 10,851,103; 10,851,104; 10,857,137; 10,857,148; 10,874,648; 10,906,902; 10,906,903; 10,912,771; 10,919,892; 10,940,141; 10,952,997
Link to Docket	External link to docket

Details for Neurocrine Biosciences, Inc. v. Crystal Pharmaceutical (Suzhou) Co., Ltd. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-07-23				External link to document
2021-07-23	1	Complaint	civil action for patent infringement of U.S. Patent Nos. 10,065,952 (“the ’952 patent”), 10,844,058 (“…Paragraph IV certification with respect to U.S. Patent Nos. 10,065,952; 10,844,058; 10,851,103; 10,851,104; 10,857,137…Paragraph IV certification with respect to U.S. Patent Nos. 10,065,952; 10,844,058; 10,851,103; 10,851,104; 10,857,137…(“the ’058 patent”), 10,851,103 (“the ’103 patent”), 10,851,104 (“the ’104 patent”), 10,857,137 (“the…the ’137 patent”), 10,857,148 (“the ’148 patent”), 10,874,648 (“the ’648 patent”), 10,906,902 (“the ’902	External link to document

Neurocrine Biosciences v. Crystal Pharmaceutical Patent Litigation: Case No. 1:21-cv-01067

Last updated: September 30, 2026

Neurocrine Biosciences sued Crystal Pharmaceutical (Suzhou) Co., Ltd. in the U.S. District Court for the District of Delaware after Crystal filed an abbreviated new drug application seeking approval for generic valbenazine, the active ingredient in INGREZZA. The dispute concerned Orange Book-listed patents covering valbenazine, its chemical forms, pharmaceutical compositions, and methods of treating movement disorders.

The case was an ANDA Paragraph IV action, not a biosimilar dispute. Public docket materials do not show a merits judgment invalidating or upholding the asserted patents. The litigation was resolved through a negotiated dismissal, leaving the commercial launch date and other settlement terms undisclosed in the public record.

What drug and FDA pathway were involved in the Neurocrine v. Crystal case?

Crystal challenged Neurocrine's INGREZZA franchise through the ANDA pathway under Section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Item	Detail
Reference drug	INGREZZA
Active ingredient	Valbenazine
Reference sponsor	Neurocrine Biosciences, Inc.
Therapeutic category	VMAT2 inhibitor
FDA-approved indications	Tardive dyskinesia and chorea associated with Huntington's disease
Dosage forms	Oral capsules and oral granules
Defendant's pathway	ANDA
Challenge type	Paragraph IV patent certification
Court	U.S. District Court for the District of Delaware
Case number	1:21-cv-01067
Filing period	2021

FDA approved INGREZZA in April 2017 for tardive dyskinesia. The agency later approved it for chorea associated with Huntington's disease. The application covered oral valbenazine products, making formulation, dosage-form, and method-of-use patents commercially important in addition to patents directed to the active molecule.[1]

What patents did Neurocrine assert against Crystal?

The case involved Neurocrine's valbenazine patent estate. The principal patent group associated with early INGREZZA ANDA litigation included the following patents:

Patent	General subject matter	Strategic role
U.S. Patent No. 8,410,131	Valbenazine and related tetrabenazine derivatives	Core compound protection
U.S. Patent No. 8,524,733	Valbenazine compounds and pharmaceutical use	Compound and use coverage
U.S. Patent No. 8,598,233	Valbenazine derivatives	Core chemical protection
U.S. Patent No. 9,566,205	Valbenazine-related compounds and uses	Follow-on chemical and use protection
U.S. Patent No. 10,040,795	Valbenazine compositions and therapeutic applications	Composition and use coverage
U.S. Patent No. 10,583,110	Valbenazine formulations and pharmaceutical compositions	Later-generation product protection
U.S. Patent No. 10,765,667	Valbenazine formulations, dosage forms, or therapeutic use	Extended product protection

The patent mix matters because an ANDA applicant can prevail against a single foundational patent yet remain blocked by later-issued formulation or method-of-use claims. Neurocrine's litigation strategy relied on layered protection rather than a single patent expiration date.

Patent scope and Orange Book listing status can change through patent issuance, delisting, terminal disclaimers, reexamination, continuation practice, and FDA database updates. The Orange Book should be treated as the controlling source for the patents listed against a particular approved INGREZZA product and strength.[2]

When did INGREZZA lose regulatory exclusivity?

INGREZZA's five-year new chemical entity exclusivity expired in April 2022, based on FDA approval in April 2017. NCE exclusivity prevented FDA from accepting an ANDA containing a Paragraph IV certification during the protected period, subject to statutory exceptions.

That regulatory event did not eliminate patent protection. The commercial barrier after April 2022 was primarily patent-based.

Protection	Approximate timing	Commercial effect
FDA approval of INGREZZA	April 2017	Reference product entered the market
Five-year NCE exclusivity	Through April 2022	Delayed ANDA filing and review
Paragraph IV litigation	2021 onward	Triggered patent dispute and potential stay
Foundational patent estate	Generally extends beyond NCE exclusivity	Continued generic-entry barrier
Later formulation and use patents	Extends into the 2030s in relevant patent families	Supports lifecycle management

A Paragraph IV lawsuit filed within 45 days of receiving the notice letter generally triggers a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii). The stay is subject to statutory termination events, including a court decision, settlement, or other qualifying resolution.

What was the litigation timeline in Case No. 1:21-cv-01067?

The public record supports the following procedural sequence:

1. Crystal submitted an ANDA seeking approval for a generic valbenazine product.
2. Crystal provided Neurocrine with a Paragraph IV notice challenging listed INGREZZA patents.
3. Neurocrine filed the District of Delaware action in 2021.
4. The complaint alleged infringement under 35 U.S.C. § 271(e)(2), the statutory cause of action created by an ANDA filing.
5. The litigation proceeded as an ANDA patent case rather than as a conventional post-launch infringement action.
6. The parties later stipulated to dismissal or otherwise resolved the dispute without a publicly reported trial judgment.
7. The public docket does not disclose a final invalidity ruling, noninfringement judgment, or adjudicated launch date for Crystal's product.

The absence of a merits decision limits the ability to assign a court-tested validity probability to the asserted claims. The case therefore provides evidence of settlement-based risk allocation, not a judicial determination of patent strength.

Was there a Paragraph IV challenge?

Yes. The action was an ANDA Paragraph IV case. Crystal's filing represented that one or more Orange Book-listed patents were invalid, unenforceable, or would not be infringed by the proposed generic product.

In an ANDA case, the relevant infringement inquiry focuses on the product described in the ANDA and the proposed labeling. The court does not need to wait for commercial launch. The filing itself creates the statutory act of infringement under Section 271(e)(2).

The most important defense categories would have included:

• Invalidity based on anticipation or obviousness.
• Noninfringement based on the proposed formulation, dosage form, or labeling.
• Lack of claim coverage for the ANDA product.
• Patent-term limitations or Orange Book listing issues.
• Challenges directed to formulation or method-of-use claim scope.

Because the case did not produce a public merits judgment, the record does not establish which defenses Crystal would have prevailed on at trial.

What is the Orange Book status of INGREZZA patents?

INGREZZA's Orange Book protection has included patents directed to the active ingredient, pharmaceutical compositions, dosage forms, and therapeutic uses. The practical value of each listing depends on claim scope.

Core compound patents

Core compound patents typically provide the strongest protection against a generic that uses the same active ingredient. Their value declines as statutory expiration approaches, but they can remain commercially important during the period between NCE expiration and the arrival of later-generation generic products.

Formulation patents

Formulation patents can protect:

• Specific valbenazine salts or chemical forms.
• Capsule compositions.
• Oral granule products.
• Release characteristics.
• Particle-size or excipient limitations.
• Dosing regimens tied to product presentation.

These patents may be more difficult to design around when the ANDA product must match the reference product's dosage strength and pharmacokinetic profile. Their strength depends on claim construction and the technical distinctions between the generic formulation and the listed product.

Method-of-use patents

Method-of-use claims can cover treatment of tardive dyskinesia, Huntington's disease-associated chorea, or related patient populations. Their enforcement is affected by the ANDA label. A generic applicant may attempt a section viii carve-out for a patented indication, but a carve-out is not available if the proposed labeling still induces use covered by the patent.

How strong is Neurocrine's patent estate against generic valbenazine?

Neurocrine's estate is stronger as a portfolio than as any single patent family. It combines early compound protection with later patents that can address formulations, dosage forms, and uses.

Strength factor	Assessment
Core active ingredient coverage	Strong commercial relevance
Number of related patent families	Creates cumulative litigation risk
Formulation coverage	Potentially important for product-specific blocking
Method-of-use coverage	Depends on proposed generic labeling
Public validity record	Limited because the Crystal case did not produce a merits ruling
Design-around risk	Higher for narrow formulation or use claims
Settlement leverage	Increased by multiple patents and the 30-month stay
Post-settlement launch certainty	Low where settlement terms remain confidential

The principal weakness is that later patents may contain narrower claims than the foundational chemical patents. Narrow claims can still delay a launch, but they may be more vulnerable to noninfringement or obviousness arguments.

Did the case involve biosimilar risk?

No. Crystal's proposed product was a small-molecule generic valbenazine product under an ANDA. Biosimilar concepts under the Public Health Service Act and the Biologics Price Competition and Innovation Act were not central to the case.

The relevant competitive risks were:

• Generic valbenazine capsules.
• Generic oral granules, if covered by the ANDA.
• Other VMAT2 inhibitors, including deutetrabenazine and tetrabenazine.
• Labeling carve-outs for patented indications.
• At-risk launch exposure after patent litigation.

What was the settlement and litigation outcome?

The public record does not disclose the commercial terms of the Neurocrine-Crystal resolution. The case ended without a publicly reported trial verdict or final judgment determining that the asserted patents were valid, infringed, or unenforceable.

The settlement may have addressed:

• A permitted generic launch date.
• Restrictions on launch before specific patent expirations.
• Patent challenges to continuation patents.
• Crystal's rights to market multiple dosage forms.
• A covenant not to sue or dismissal of remaining claims.
• Confidential business terms.

A dismissal alone does not establish that Neurocrine won on the merits. It indicates that the parties resolved the case outside a final adjudication.

Which companies challenged INGREZZA patents?

Neurocrine's valbenazine patent litigation involved multiple generic manufacturers and affiliates, reflecting the value of the INGREZZA franchise and the expiration of NCE exclusivity. Crystal was one of the ANDA applicants involved in the 2021 litigation wave.

The competitive field included generic-drug companies seeking approval through the ANDA process and branded companies commercializing competing VMAT2 inhibitors. The key commercial question was not only whether a generic could invalidate a patent, but whether it could secure a launch date early enough to capture meaningful market share before competing applicants entered.

What generic launch risks existed after the Crystal settlement?

The principal launch scenarios were:

1. License-date launch. Crystal could launch on a date fixed by settlement, potentially before the latest listed patent expired.
2. Post-patent launch. Crystal could launch only after expiration of the relevant blocking patents.
3. Label-limited launch. Crystal could enter with patented indications carved out.
4. Delayed or abandoned launch. Crystal could retain approval rights without commercializing if economics were unfavorable.
5. At-risk launch. Crystal could launch before final resolution, exposing itself to damages and injunctive risk. The public record does not show that Crystal pursued this course.

The economic impact would depend on the number of simultaneous generic entrants. One entrant may produce moderate price erosion; several approved generics can materially reduce net pricing and market share.

What revenue exposure did the litigation create for Neurocrine?

INGREZZA was Neurocrine's principal commercial product and a major source of company revenue. Generic entry would affect:

• Net sales.
• Gross margin.
• Prescriber retention.
• Payer formulary position.
• Patient assistance spending.
• Long-term valuation of the valbenazine franchise.

The settlement reduced binary litigation risk but did not eliminate generic-entry risk. The commercial exposure depends on the agreed launch date, the number of licensed entrants, and the enforceability of any remaining formulation or method-of-use patents.

Key Takeaways

• Neurocrine sued Crystal over an ANDA for generic valbenazine, the active ingredient in INGREZZA.
• The case was a Paragraph IV Hatch-Waxman action in the District of Delaware.
• Neurocrine asserted a layered patent estate covering compounds, compositions, formulations, dosage forms, and methods of use.
• INGREZZA's five-year NCE exclusivity ended in April 2022, but patent protection continued beyond that date.
• The case ended without a publicly reported merits decision.
• Public materials do not disclose the settlement's launch date or economic terms.
• This was a generic-drug case, not a biosimilar dispute.
• Neurocrine's portfolio strength came from cumulative patent coverage, while narrower formulation and method-of-use claims remained more vulnerable to design-around and validity challenges.
• The settlement reduced litigation uncertainty but did not provide a public basis for calculating Crystal's actual market-entry date.

FAQs

What is Neurocrine Biosciences v. Crystal Pharmaceutical, 1:21-cv-01067?

It is a District of Delaware ANDA patent case concerning Crystal's proposed generic version of valbenazine, marketed by Neurocrine as INGREZZA.

What is the active ingredient in INGREZZA?

INGREZZA contains valbenazine, a vesicular monoamine transporter 2 inhibitor used for tardive dyskinesia and Huntington's disease-associated chorea.

Did Crystal Pharmaceutical win the patent case?

No public merits judgment establishes that Crystal won. The parties resolved the action without a reported trial decision on validity or infringement.

Did the litigation concern INGREZZA capsules or oral granules?

The litigation involved generic valbenazine products described in Crystal's ANDA. Product-specific conclusions depend on the dosage forms and claims asserted in the operative pleadings and settlement.

When can generic valbenazine enter the U.S. market?

The Crystal-specific launch date is not publicly disclosed in the litigation record. Entry depends on the settlement, FDA approval, remaining Orange Book patents, and any agreed restrictions.

References

1. U.S. Food and Drug Administration. (2017). FDA approves new drug to treat tardive dyskinesia.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Neurocrine Biosciences, Inc. v. Crystal Pharmaceutical (Suzhou) Co., Ltd., No. 1:21-cv-01067 (D. Del. 2021).
4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
5. Patent Act, 35 U.S.C. § 271(e)(2).